Stock Analysis
Insulet CorporationPODD
P/E 26.07×· 5Y range 24.11–38,579.67×· bottom 3% of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsBuy33 analystsP/E 26.1× sits at the 3rd percentile of its 5.086926762491444-year history.
Cash covers 56% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Growth100
- Profitability85
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 4.8 — safe-zone balance sheet
- ✓ROE 26.4% — efficient capital deployment
- ✓Revenue CAGR 25.3% — durable top-line growth
- ✓P/E 26.1× at bottom 3% of 5-year history
What's happening with PODD
Profile
Strong growth, profitability, earnings quality and financial health; moat lags behind.
How is each axis scored?
- Valuation69/100 · Moderate
- P/E vs own history (3th pct)25/25
- FCF yield (3.0%)12/25
- P/S (3.2x)20/25
- EV/EBIT (19.8x)12/25
- Growth100/100 · Strong
- Revenue CAGR (25.3%)25/25
- Net income CAGR (95.8%)25/25
- EPS CAGR 5Y (93.5%)25/25
- Fwd implied growth (36.1%)25/25
- Profitability85/100 · Strong
- ROIC (22.2%)20/25
- ROE (26.4%)25/25
- Net margin (12.3%)20/25
- Operating margin (16.9%)20/25
- Financial Health80/100 · Strong
- Altman Z (4.77)25/25
- Current ratio (2.48)25/25
- Interest coverage (5.3x)18/25
- Net cash / debt (D/A 13%)12/25
- Quality82/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.83)25/25
- FCF conversion (78%)15/25
- Margin stability (σ 6.9%)20/25
- Moat31/100 · Weak
- ROIC >12% years (3/10 yrs)6/25
- Median gross margin (65.4%)25/25
- FCF-positive years (3/10 yrs)0/25
- Worst-year net margin (worst -7.9%)0/25
Risk Flags
- ⚠2 loss-making years in recent history
About Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. Show more
The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Headquarters: ACTON, MA · Employees: 5,400 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
69BP/E (TTM)26.0xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 24.1x–38579.7x · 3rd pct
P/FCF35.9xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.0%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -1.2%–4.3% · 94th pct
P/S (TTM)3.20xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 3.0x–20.6x · 2nd pct
EV/EBIT19.8xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 18.3x–336.8x · 12th pct
EV/Sales3.6xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E19.1xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio6.88xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.12B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
85AROIC22.2%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE26.4%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA7.5%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin12.3%A
Grade A: HighNet Income / Revenue
Operating Margin16.9%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin71.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin9.6%C
Grade C: AverageFCF / Revenue
True FCF Margin7.1%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
100A+Revenue CAGR25.3%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR95.8%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)93.5%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth36.1%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+4.4%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income20.8%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue2.6%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
80AAltman Z-Score4.77A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.48xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.81xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage5.3xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment1.4yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.8xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.67xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.56xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
82APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.83A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion78.3%C
Grade C: AverageFCF / Net Income
Margin Stability6.9%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue7.1%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.82xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Pease Flavia Filed | Pease Flavia | Tax withholding | -1882 | |
MAZELSKY JONATHAN JAY Filed | MAZELSKY JONATHAN JAY | Grant / award | +141 | |
Huffines Robert Luther Filed | Huffines Robert Luther | Grant / award | +178 | |
McEvoy Ashley Filed | McEvoy Ashley | BuyOpen market buy | +1.1K | |
Davis Lisa Blair Filed | Davis Lisa Blair | Tax withholding | -244 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
MAZELSKY JONATHAN JAY Filed | MAZELSKY JONATHAN JAY | Grant / award | +1.4K | |
Huffines Robert Luther Filed | Huffines Robert Luther | Grant / award | +144 | |
Huffines Robert Luther Filed | Huffines Robert Luther | Grant / award | +151 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
31DROIC >12% Years3/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)65.4%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years3/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-7.9%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$5.41
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$10.17
Cash & short-term investments per share (Finnhub)
Book Value / Share$21.53
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$948.40M
Total debt obligations (short + long term)
Cash & Equiv.$534.90M
Cash and short-term investments
Net Debt$413.50M
Total Debt minus Cash. Negative = Net Cash position
Total Equity$1.42B
Shareholders' equity (book value)
Asset / Liability1.82xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$9.78B
Current Market Capitalization
Beta1.09B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Insulet Corporation (PODD)
PODD is up 1.68% at the last close. Insulet Corporation meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 4.77 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.83 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 25% annually, with net income growing about 96% per year — a strong growth profile.
- Takes ~1.4 years to repay net debt from free cash flow.
- Insulet Corporation posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
- Return on equity of 26.4% is well above the market average.
See how PODD ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all PODD moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Pre-market | 140.00 | +4.53% | 3.07 |
| Oct 15 | Regular | 138.47 | +3.39% | 2.36 |
| Oct 14 | After-hours | 133.93 | -3.04% | -2.15 |
| Oct 12 | Regular | 140.00 | +3.49% | 2.97 |
| Oct 12 | After-hours | 139.81 | +3.35% | 2.86 |
Frequently Asked Questions about PODD
What is the current Insulet Corporation (PODD) stock price?
PODD is trading at $141.10 at the last market close, up 1.68% on the session. PreMarketPrice tracks PODD pre-market, intraday and after-hours prices.
Is PODD stock a buy right now?
PreMarketPrice's quantitative model rates Insulet Corporation's financial health at 80/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is PODD stock overvalued?
Insulet Corporation trades at a trailing P/E of 26.0 and our valuation score rates it 69/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Insulet Corporation report earnings?
No confirmed earnings date is currently scheduled for PODD. The Earnings section lists recent reports and updates as dates are announced.
What sector does Insulet Corporation operate in?
Insulet Corporation operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Insulet Corporation do?
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use.
About Insulet Corporation (PODD) Stock
Insulet Corporation (PODD) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Insulet Corporation is trading at $141.10, up 1.68% on the day with a market capitalization of $9.8 billion. The financial health score for PODD is 80/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for PODD stock.
PODD Stock Analysis & Key Metrics
On PreMarketPrice, you can track Insulet Corporation (PODD) across multiple dimensions:
- Pre-market price & movement: Real-time PODD stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for PODD with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Insulet Corporation across multiple reporting periods.
- Financial health score: A composite score of 80/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for PODD.
- Sector peers: Compare PODD against 6 other healthcare stocks on key financial metrics.
Is PODD a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Insulet Corporation (PODD) as an investment. The financial health score of 80/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Insulet Corporation (PODD) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.